{"id":"W2166934777","doi":"10.1210/jc.2015-1520","title":"Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial","year":2015,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université du Québec à Chicoutimi; Université de Montréal","funders":"Amarin Corporation; Ipsen; Regeneron Pharmaceuticals; Eisai; Daiichi Sankyo Europe; Sanofi; Genentech; Bristol-Myers Squibb; AstraZeneca; Daiichi-Sankyo; Amgen; Pfizer","keywords":"Alirocumab; Atorvastatin; PCSK9; Ezetimibe; Rosuvastatin; Medicine; Pharmacology; Regimen; Internal medicine; Statin; Urology; Cholesterol; Apolipoprotein B; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005975616,0.0002960103,0.002636983,0.0001802446,0.0000993231,0.00002850927,0.0003048458,0.0001709005,0.0002277914],"category_scores_gemma":[0.0043813,0.000150792,0.001535659,0.0001892638,0.0003149809,0.0001000764,0.00005172009,0.0007738237,0.0002541893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009092382,"about_ca_system_score_gemma":0.001603,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004148121,"about_ca_topic_score_gemma":0.00003269148,"domain_scores_codex":[0.9933138,0.003119323,0.002004918,0.0002518304,0.0008115839,0.0004985203],"domain_scores_gemma":[0.9951813,0.002081468,0.0007673869,0.0007800789,0.0004504915,0.000739284],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9445079,0.0007558228,0.000005543736,0.000005329198,0.002477315,0.00008875116,0.0005687975,0.0001458107,0.00001844479,0.008716271,0.001720307,0.0409897],"study_design_scores_gemma":[0.7287447,0.007948002,0.0002094781,0.00003374219,0.002269281,0.0003022348,0.0009866239,0.00000767685,0.0001461661,0.0009463197,0.2582912,0.0001146592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710103,0.003990659,0.0005806521,0.01147828,0.005674857,0.002007897,0.000008626537,0.0000389049,0.005209785],"genre_scores_gemma":[0.9664902,0.007076844,0.002520369,0.005315993,0.01707344,0.0001306006,0.000004775019,0.00007936563,0.001308397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2565708,"threshold_uncertainty_score":0.614912,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1373651670151855,"score_gpt":0.4489970766668255,"score_spread":0.31163190965164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}